Improving Visual Perception and Visuo-motor Learning With Neurofeedback of Brain Network Interaction.
Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Feb 8, 2023
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new way to improve how the brain communicates during tasks that involve seeing and moving. Researchers are investigating a technique called neurofeedback, which gives people real-time information about their brain activity. This feedback helps individuals learn to enhance the communication between different parts of their brain when they are at rest, which may lead to better visual perception and motor learning when they do engage in tasks.
To participate in this study, you need to be at least 18 years old and have normal or corrected vision. You should not have any neurological or psychiatric conditions, and you should not regularly use certain medications that affect the brain. Participants will receive guidance on how to use neurofeedback to potentially improve their brain function. If you’re interested in being part of this exciting research, it’s a chance to contribute to understanding how we can train our brains to work better together!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Signed informed consent
- • Age at least 18 years old
- • Normal or corrected-to-normal vision
- • No neurological or psychiatric diseases
- • No regular consumption of benzodiazepines or neuroleptics
- Exclusion Criteria:
- • Any surgical intervention to the brain
- • Drug or alcohol abuse
- • Presence of non-MRI safe metal in the body
About Insel Gruppe Ag, University Hospital Bern
Insel Gruppe AG, the umbrella organization for the University Hospital Bern, is a leading healthcare provider in Switzerland, renowned for its commitment to advancing medical research and patient care. As a key player in clinical trials, Insel Gruppe AG integrates cutting-edge scientific inquiry with clinical excellence, facilitating innovative studies that span a wide range of medical disciplines. The institution prioritizes collaboration with academic partners and industry stakeholders to enhance the understanding of diseases and develop effective treatment options, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bern, , Switzerland
Patients applied
Trial Officials
Adrian Guggisberg, Prof. Dr.
Principal Investigator
Division of Neurorehabilitation, Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Switzerland.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials